Acta Ophthalmol by FINGER, R. P. et al.
Review Article
A novel tool to assess the quality of RWE to guide
the management of retinal disease
Robert P. Finger,1 Vincent Daien,2,3 James S. Talks,4 Paul Mitchell,5 Tien Y. Wong,6,7
Taiji Sakamoto,8 Bora M. Eldem,9 Monica L€ovestam-Adrian10 and Jean-Francois Korobelnik11,12
1Department of Ophthalmology, University of Bonn, Bonn, Germany
2Department of Ophthalmology, Gui De Chauliac Hospital, Montpellier, France
3The Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia
4Department of Ophthalmology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
5Center for Vision Research, Westmead Institute for Medical Research, University of Sydney, Sydney, NSW, Australia
6Singapore Eye Research Institute, Singapore National Eye Center, Singapore, Singapore
7Duke-NUS Medical School,Singapore, Singapore
8Department of Ophthalmology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, and J-
CREST, Japan
9Faculty of Medicine, Ophthalmology Department, Hacettepe University, Ankara, Turkey
10Department of Ophthalmology, Lund University Hospital, SUS Lund, Sweden
11CHU Bordeaux, Service d’Ophtalmologie, France
12Univ. Bordeaux, INSERM, BPH, U1219, Bordeaux, FranceOpen access funding enabled and organized by Projekt DEAL.
ABSTRACT.
Despite the growing importance of real-world evidence (RWE) for guiding
clinical decisions in retinal disease, there is currently no widely used guidance
available for assessing the quality and relevance of RWE studies in ophthal-
mology. This paper summarizes the development of a user-friendly tool that
facilitates assessment of the quality of available RWE for neovascular age-
related macular degeneration (nAMD), diabetic macular oedema (DME) and
retinal vein occlusion (RVO). A literature search was conducted to identify tools
developed to assess the quality of RWE, in order to identify the most appropriate
framework on which to base this tool. The Good Research for Comparative
Effectiveness (GRACE) guidelines was chosen for this purpose as it is designed
to assess the quality of observational studies and has been extensively validated,
including demonstration of strong sensitivity and specificity. The GRACE
guidelines were adapted to develop a straightforward tabular tool that allows
simple assessment and comparison of the quality of published evidence in retinal
disease for researchers and physicians alike, and includes guidance on treatment
details, outcome measures, study population, and controlling for bias. The newly
developed tool provides a simple method to support assessment of the strength of
evidence and certainty of conclusions drawn from RWE in retinal disease, to
ensure clinical decision-making is influenced by the highest quality evidence.
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RWE is becoming increasingly impor-
tant to complement data from random-
ized clinical trials (RCTs) and to
provide insights that are outside their
remit (de Lusignan et al. 2015; Talks
et al. 2019). Additionally, RWE is
increasingly considered and recognized
by healthcare authorities as meaningful
information to inform regulatory deci-
sions, develop guidelines and demon-
strate value (ABPI 2011; US Food &
Drug Administration 2020). Sources of
RWE include registries, records, claims
databases, observational or longitudi-
nal cohort studies and health surveys
(de Lusignan et al. 2015; Mehta et al.
2018; Talks et al. 2019). These sources
reflect routine clinical practice, so can
confirm and complement results from
RCTs by assessing their applicability in
a more general population (Mehta
et al. 2018; Talks et al. 2019).
Specifically, sources of real-world
data (RWD) used to generate RWE
include wider, more heterogeneous
patient groups, including those with
co-morbidities, those receiving con-
comitant therapies and those with
baseline factors known to impact
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treatment outcomes, who might not be
included in RCTs due to rigorous
selection criteria (de Lusignan et al.
2015; Talks et al. 2019). RWE can
reflect variations in adherence or treat-
ment access due to resource con-
straints, detect less common and later-
onset adverse effects by examining
treatment effectiveness over the longer
term, and can include a broader range
of endpoints more pertinent to routine
clinical practice than RCTs (de Lusig-
nan et al. 2015; Hoque et al. 2016;
Mehta et al. 2018; Talks et al. 2019).
Primary outcomes in RWE studies may
include clinical effectiveness and safety,
patterns of treatment use, resource
utilization, cost, adherence and persis-
tence, patient burden or patient-re-
ported outcomes (e.g. quality of life
[QoL]) and treatment satisfaction) (de
Lusignan et al. 2015; Talks et al. 2019).
In the context of retinal disease,
there is a growing wealth of RWE that
has investigated the use of anti-vascu-
lar endothelial growth factor agents
(anti-VEGFs) in clinical practice, fol-
lowing their development as a major
therapeutic advance (Talks et al. 2019).
In the context of nAMD, RWE has
uncovered issues regarding the imple-
mentation of various treatment strate-
gies in practice. This has led to research
into optimizing anti-VEGF dosing reg-
imens, with the aim of balancing clin-
ical outcomes and treatment burden to
achieve optimal long-term outcomes
for patients (Daien et al. 2020 [in
preparation]). Specifically, RWE sup-
ports proactive treat-and-extend (T&E)
dosing of anti-VEGFs to optimize
visual outcomes, while minimizing
injection frequency (Hanemoto et al.
2017). However, RWE has also
revealed that delay in the diagnosis
and treatment of retinal disease is
common, which often leads to subop-
timal visual outcomes (Arias et al.
2009; Cavan et al. 2017).
The growing importance of RWE in
retinal disease means that clinicians,
payers and other stakeholders should
consider implementing relevant findings
into clinical practice (Talks et al. 2019).
However, there are inherent limitations
to data collection in real-world clinical
practice, and as a result, RWEmay vary
in quality. In particular, outside the
stringently controlled environment of
anRCT, specific biases can occur, which
necessitate appropriate study design
and statistical analysis (de Lusignan
et al. 2015; Dreyer et al. 2016; Talks
et al. 2019). Without appropriate eval-
uation of study quality, clinical deci-
sions may be taken based on evidence
that is not sufficiently robust (Garrison
et al. 2007).
A systematic review found that there
was no consensus on a preferred
instrument for assessing RWE (Briere
et al. 2018), although some resources to
support evaluation of the quality of
ophthalmology-specific RWE exist.
For example, the International Con-
sortium for Health Outcomes Measure-
ment (ICHOM) has defined a
minimum set of standardized and
patient-oriented outcome measures
that should be collected and reported
as RWD associated with macular
degeneration (Rodrigues et al. 2016).
The lack of consensus on how to define
quality in this setting can make RWE
interpretation difficult for ophthalmol-
ogy clinicians, and a framework to
facilitate systematic assessment of
RWE quality and relevance – specifi-
cally concerning intravitreal anti-
VEGFs – would be valuable. Inclusion
of retinal disease-specific considera-
tions when collecting RWD would help
ophthalmologists to more accurately
assess the RWE quality relating to the
use of anti-VEGF therapies.
This paper summarizes the develop-
ment of a user-friendly framework that
facilitates assessment of the quality of
available RWE for nAMD, DME and
RVO. The framework will allow oph-
thalmologists to independently draw
relevant and reliable conclusions from
RWE in retinal disease.
METHODS
Literature review
A literature search was conducted on 1
December 2018, to identify tools devel-
oped to assess the quality of RWE,
irrespective of clinical indication or
setting, using the following search
terms: (Checklist OR tool OR assess*
[tiab] OR apprais*[tiab] OR score[tiab]
OR ‘Checklist’[Majr]) AND ((‘real-
world data’ OR ‘real-world evidence’
OR ‘real-world outcomes’ OR ‘Obser-
vational Studies as Topic’[Majr] OR
‘Epidemiologic Studies’[Majr]) NOT
‘Randomized Controlled Trial’ [Publi-
cation Type]). PubMed was used for
automated searching of the indexed
literature in MEDLINE, which was
limited to English language publica-
tions within the last 5 years. Abstracts
were scanned for appropriateness using
preagreed inclusion and exclusion cri-
teria, and full-text copies of articles
that were accepted after the initial
screening were reviewed and assessed
for eligibility. Following full-text
review, articles deemed eligible for
inclusion were accepted. In addition, a
search was performed on Google and
of ISPOR abstracts to supplement the
indexed literature search.
Collaboration with panel of experts
The authors of this article comprise a
steering committee of experts in the
field of RWE and ophthalmology.
Having discussed the results of the
literature review during a series of
meetings and online surveys, the most
appropriate tool to be used as a
framework for assessing RWE for reti-
nal disease was decided on. Once the
framework was established, considera-
tions specific to assessing the quality of
RWE in retinal disease were discussed
and added alongside the existing tool
framework, to support recommenda-
tions on how the tool should be used
when assessing RWE in retinal disease.
These recommendations comprise the
observations, guidance, and clinical
and research experience of the authors,
who have generated and published
RWE in retinal disease extensively.
RESULTS
Literature review
The literature review identified 39 arti-
cles, describing 13 tools for evaluating
quality of RWD used to generate RWE
(Downs & Black 1998; Berger et al.
2014; Dreyer et al. 2014; Roche et al.
2014; BMJ Clinical Evidence Blog
2015; Malmivaara 2015; Downes et al.
2016; Dreyer et al. 2016; Malmivaara
2016; Rao et al. 2016; Briere et al. 2018;
Camm et al. 2018; CASP UK 2018;
Miksad & Abernethy 2018; Schaum-
berg et al. 2018; CASP UK 2018;
Scottish Intercollegiate Guidelines Net-
work 2019; Ottawa Hospital Research
Institute 2020); 11 tools for reporting
RWD collection and study design
(Stroup et al. 2000; von Elm et al.
2007; Berger et al. 2009; Loring &
Bowden 2014; Vandenbroucke et al.
2014; Benchimol et al. 2015; Bennett
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et al. 2015; Fitchett et al. 2016; Lachat
et al. 2016; Langan et al. 2016; Morton
et al. 2016; Agha et al. 2017; Horby
et al. 2017; Hornell et al. 2017; Sharp
et al. 2017; Yang et al. 2017; European
Network of Centres for Pharmacoepi-
demiology & Pharmacovigilance 2018;
Pandey et al. 2018; Patient-Centred
Outcomes Research Institute 2019);
and two tools to aid statistical analysis
(Sauerbrei et al. 2014; VanderWeele &
Ding 2017). Therapy area-specific tools
and guidelines for reporting RWD and
study design were generally extensions
of STROBE. None were identified as
being ophthalmology-specific.
Rationale for using the GRACE checklist
as the basis of the retina-specific RWE
quality tool
The steering committee identified a
published RWE quality checklist from
the literature review (the GRACE
guidelines) (Dreyer et al. 2016) for
adaptation and inclusion of retinal
disease-specific considerations. The
steering committee agreed that
GRACE was the most appropriate
framework for the retina-specific tool
as it is designed to assess the quality of
observational studies and has been
extensively validated, including demon-
stration of strong sensitivity and speci-
ficity. Other checklists identified by the
literature review were typically
restricted to the assessment of evidence
generated from certain designs of real-
world study. The STROBE checklist,
and its extensions, were discounted as a
framework as they are tools to guide
the reporting of RWD, aimed at
authors preparing a manuscript for
publication, rather than assessing pub-
lished data.
Guidance on RWE quality
The original GRACE checklist (Dreyer
et al. 2016) was adapted to ensure
relevance to the ophthalmological com-
munity. In doing so, some questions
were combined or omitted and some
minor modifications made to wording.
Specifically, ‘Was the primary clini-
cal outcome(s) measured objectively
rather than subject to clinical judg-
ment?’ was combined with ‘Were pri-
mary outcomes validated, adjudicated,
or otherwise known to be valid in a
similar population?’, and ‘Were impor-
tant covariates that may be known
confounders or effect modifiers avail-
able and recorded?’ was combined with
‘Were important confounding and
effect-modifying variables taken into
account in the design and/or analysis?’
This was done in an effort to bring
similar concepts together as single
questions, thereby increasing the sim-
plicity of the tool.
‘Was the study (or analysis) popula-
tion restricted to new initiators of
treatment or those starting a new
course of treatment?’ was adapted sig-
nificantly to ‘’Was the study popula-
tion relevant to the research question
and clinical practice?’ This was driven
by the fact that many patients with
retinal disease are previously treated or
currently on a course of treatment at
the start of observation in real-world
studies – as such, this does not neces-
sarily preclude high-quality research in
this therapy area.
Finally, ‘Is the classification of
exposed and unexposed person-time
free of ‘immortal time bias’?’, a concept
that can be challenging to assess with-
out a thorough methodological review,
was omitted.
The resulting tool to aid assessment
of the quality of RWE in retinal disease
is outlined in Table 1. To provide
context and background information
relevant to the checklist questions,
detailed guidance on retinal disease-
specific criteria to consider when
assessing the quality of RWE has been
included.
Treatment details
It is important that information on the
various treatments administered in the
studies is defined in detail, as regimens
are often interpreted and applied dif-
ferently between clinics, and this may
influence outcomes.
Outcome measures
It is important to consider if the
reported outcomes of a RWE study
are appropriate to answer the research
question and relevant to clinical prac-
tice. The primary endpoint should also
be captured appropriately and accu-
rately, with the likelihood of missing
outcome values from the RWD source
considered.
The study design should incorporate
a duration of follow-up adequate to
measure the outcome of interest.
nAMD, DME and macula oedema
secondary to RVO are chronic diseases
(Schmidt-Erfurth et al. 2019), so suffi-
cient time should be allowed to assess
long-term effects of treatment. For
example, a study with a follow-up of
6 months may be useful to assess the
early effectiveness of anti-VEGF load-
ing doses on vision outcomes, but
conclusions on the long-term impact
of continued anti-VEGF dosing on
maintenance of vision should not be
drawn from these data. At least 1 year
of follow-up should be available to
assess the effectiveness of a treatment
and dosing regimen, and longer follow-
up is required to draw valid conclu-
sions when comparing different treat-
ment regimens (e.g. T&E vs PRN).
Outcomes should be measured using
standardized and validated methods,
and/or undergo independent validation
or systematic adjudication. A clinical
outcome can be considered objectively
measured if it is assessed using a
standardized test; it is not objectively
measured if it is based on a physician’s
opinion or observation.
Outcomes should be measured in an
equivalent manner, using the same
method and measurement, across com-
parison groups to provide uniformity
and allow for a like-for-like assessment
of outcomes, wherever possible. If the
study design necessitates the use of
different methods or measurements, the
method used to transform the data to
ensure comparability should be fully
described and any limitations acknowl-
edged.
Study population
The study population should represent
the typical range of patients seen in
clinical practice. In addition, it is impor-
tant to consider the setting/environment
of the population to ensure applicability
to other cohorts of patients. For exam-
ple, healthcare systems can differ signif-
icantly between regions, and public and
private systems, which may introduce
differences in treatment patterns that
potentially affect outcomes. Data from
a single centre may be less generalizable,
whereas a multi-national, multi-centre
study could provide data from several
settings and may be more widely appli-
cable.
Patient numbers can affect the sta-
tistical weight and applicability of any
RWE findings. Larger patient numbers
increase the reliability of the data set;
however, the exact number of patients
required to ensure reliability of
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Table 1. Retinal disease-specific tool to evaluate the quality of RWE
Quality assessment question Retinal disease-specific considerations Checklist
Treatment
details
Were important details of treatment
exposure adequately recorded for the
study purpose in the data source(s)?
Treatment details should include:
• Name of treatment and dose
• Treatment strategy/regimen (e.g. T&E, fixed dose, pro re nata
[PRN], including length of treatment intervals, criteria for
decision-making, and frequency of monitoring, if applicable)





Were the primary outcomes adequately
recorded for the study purpose (can the
primary outcome adequately address the
research question)?
Examples of appropriate use of outcomes include:
• Change in visual acuity from baseline to assess effectiveness of
therapy
• Claims data reporting on the cost of treatment to assess
economic burdenAn example of an inappropriate use of
outcomes includes:
• Injection number to assess the overall cost of treatment, without
accompanying system-wide cost analysisIn retinal disease, it is
also important to distinguish if differences in outcomes are
statistically and/or clinically significant
• The proportion of patients reaching a visual acuity that allows
them to read or drive is often considered as the most clinically
relevant endpoint. In addition, a change in visual acuity of 10–15
ETDRS letters is generally accepted as clinically significant
Yes
No
Was the primary outcome measured
objectively, and adjudicated/validated
where required?
Examples of objective methods to measure outcomes in retinal
disease include:
• ETDRS letters, Snellen equivalent or LogMAR to measure
visual acuity
• National Eye Institute Visual Function Questionnaire-25 (NEI
VFQ-25) to measure quality of life
• Independent adjudication of OCT images by a reading centre, to
confirm diagnoses or the presence of retinal fluid
Yes
No
Were outcomes measured or identified in
an equivalent manner between treatment
groups?
Where possible, outcomes should be measured using the same
method
• For example, visual acuity scores should be measured using
either ETDRS or LogMAR, and uniformly with or without
correctionExamples of when the use of different methods may be
necessary include:
• If equipment used for OCT varies across sites in a multi-centre
study
• If disease activity is defined differently between clinics or
physicians, e.g. varying amounts of retinal fluid observed on





Was the study population relevant to the
research question and clinical practice?
The population in the study should closely reflect the patients seen
in clinical practice to ensure translatability of conclusions
Whether patients are treatment-na€ıve or treatment-experienced can
affect outcomes. However, it is common for patients with retinal
disease to switch treatments or treatment regimens, and it is
therefore appropriate for a study to include patients who are
treatment-na€ıve or treatment-experienced
• For treatment-experienced patients, the duration of prior




If one or more comparison groups were
used, were they concurrent comparators?
If not, did the authors justify the use of
historical comparison group(s)?
Treatment approaches and the standard of care for retinal disease
used in clinical practice have differed significantly over time;
therefore, the era in which the study was conducted should be
taken note of
• The use of historical comparators in retinal disease is often not
justified, and without a concurrent comparator, the impact of
any data is reduced significantly
□Yes
□No
Controlling for bias Were important covariates, confounding,
and effect-modifying variables taken into
account in the design and/or analysis?
If confounding variables that may affect outcomes between
treatment groups are present (e.g. differences in baseline visual
acuity between groups), these should be appropriately adjusted for
using statistical analyses to minimize the risk of bias
Variables that might affect outcomes in retinal disease include:
Age, gender, smoking status, concomitant conditions and





conclusions depends on the research
question being assessed. The statistical
power of the data set used should be
described and associated power calcu-
lations reported.
The standard epidemiological
approach is to restrict a study popula-
tion to new initiators of treatment
when comparing outcomes between
treatment groups. However, since
patients with retinal disease commonly
switch treatments (e.g. from ranibizu-
mab to aflibercept, or vice versa) or
treatment regimens (e.g. from PRN to
T&E) in real life, it is appropriate for a
study to include patients who switch
from one therapy to another, if appro-
priately accounted for in both the study
design and analysis.
The rapid evolution of available
therapies and dosing regimens for the
treatment of retinal disease means the
management landscape has changed
markedly over the past decade, which
could influence outcomes and subse-
quent conclusions if comparing treat-
ment during different time periods.
Ideally, data relating to all comparison
groups should be captured concur-
rently in the same observation period,
and historical comparisons should be
avoided; if a study undertakes a his-
torical comparison, it should be justi-
fied and resulting limitations
acknowledged. Studies incorporating
historical comparators, such as those
comparing outcomes in the same
patients who switch from one treat-
ment or regimen to another or exam-
ining the impact of revised treatment
guidelines on patient outcomes, should
note whether the patients or eyes fol-
lowed in the first and subsequent
treatment periods are the same and, if
not, should state if baseline character-
istics are similar between the popula-
tions being compared. In addition, the
limitations of the historical approach
should be appropriately considered and
include reference to any change in the
standard of care for patient monitoring
or postinjection aftercare, which could
affect treatment outcomes.
Controlling for bias
Confounding refers to an association
between an exposure and an outcome
being distorted by the presence of
another variable (Talks et al. 2019).
The confounding variable may exert a
measurable effect, which could either be
recorded as an association between an
exposure and an outcome where none
exists, or diminish a true association
(Norgaard et al. 2017). All variables
that could affect outcomes should be
accurately recorded as part of reporting
RWE and, if confounding variables are
present, adjustments should be made
using appropriate statistical analyses to
minimize the risk of bias.
It is important that patients are
followed appropriately to record the
course of their disease, and how it
changes over time and with treatment.
How patients were followed over the
course of study, and how patient loss to
follow-up was addressed should be
clearly stated. Drop-out rates should
be taken into account when
interpreting study results and be dis-
cussed in the conclusions, if appropri-
ate. Insight into reasons for patient
drop-out is also valuable and should be
collected and reported where possible.
Analyses to assess the potential for a
biased evaluation of exposure or out-
come should be performed. Sensitivity
analyses and stratified or subgroup
analyses can be performed to test key
assumptions on which study results are
based. In retinal disease, these may take
into account, for example, differences in
baseline patient characteristics such as
visual acuity, patient age or prior
treatment at study start. Subgroup
analyses according to postbaseline fac-
tors, such as number of injections
received, should be interpreted with
caution since it is difficult to control
for inherent bias in such factors.
Discussion and
conclusions
Intravitreal anti-VEGFs are the stan-
dard of care for nAMD, DME, RVO
(Schmidt-Erfurth et al. 2014; Schmidt-
Erfurth et al. 2017; Schmidt-Erfurth
et al. 2019). While data from RCTs
provide valuable insights into disease
management, the controlled treatment
protocols and selective patient popula-
tions may not reflect real-world clinical
practice (de Lusignan et al. 2015;
Mehta et al. 2018; Mulder et al. 2018;
Talks et al. 2019). RWE has already
contributed to the optimization of anti-
VEGF therapy for retinal disease in the
Table 1 (Continued)
Quality assessment question Retinal disease-specific considerations Checklist
Specifically in DME, variables that might affect outcomes include:
Diabetes disease characteristics (glycemic control, duration of
diabetes), blood pressure and characteristics of macular oedema
(macular thickness, extension of oedema and presence of hard
exudates)
Specifically in nAMD, variables that might affect outcomes
include:
Presence of PCV and duration of visual symptoms
Specifically in RVO, a variable that might affect outcomes includes
duration of macular oedema and subsequent photoreceptor
damage
Were any meaningful analyses conducted
to test key assumptions on which
primary results are based?
Sensitivity, subgroup and stratified analyses may be used to further
test the robustness of primary research findings
□Yes
□No
DME = diabetic macular oedema; ETDRS = Early Treatment Diabetic Retinopathy Study; nAMD = neovascular age-related macular degener-




real world and has the potential to
address other important clinical ques-
tions. Therefore, RWE is of increasing
importance in the field of ophthalmol-
ogy (Talks et al. 2019). Here, we report
the development of a tool to support
evaluation of the quality of RWE
studies, to ensure only reliable conclu-
sions from robust, good-quality evi-
dence are translated to everyday
clinical practice.
Rather than create a new tool, the
published GRACE checklist (Dreyer
et al. 2016) has been used as a frame-
work, with permission of the GRACE
authors, and with adaptations to incor-
porate details specific to the quality of
RWE in retinal disease, based on
opinion of this group of leading experts
in the field of opthalmology. While this
retinal disease-specific tool is closely
based on the GRACE checklist, which
has been extensively validated and is
robustly sensitive and specific, ideally
the adaptation should be further vali-
dated through a Delphi consensus or
similar robust method. This would
further increase its utility to identify
high-quality observational comparative
RWE in the field of retinal disease that
is applicable for decision support.
In nAMD, DME and RVO, a global
consensus on the requirements to clas-
sify RWE as high quality would facil-
itate balanced comparison of published
results (Mehta et al. 2018). The
ICHOM has previously defined a min-
imum set of standardized and patient-
oriented outcome measures that should
be collected and reported as RWD on
macular degeneration (Rodrigues et al.
2016), which is valuable to guide out-
come collection for those generating
RWD in the field. However, the tool
reported here goes further to outline
guidance to aid the assessment of the
standard for RWD collection and
analysis in retinal disease, covering
the full range of aspects that should
be considered, including study design
and controlling for bias. The straight-
forward tabular format allows simple
assessment and comparison of the
quality of published evidence for
researchers and physicians alike. In
particular, this tool provides practising
physicians with a simple method to
support assessment of the strength of
evidence and certainty of conclusions
drawn from RWE in retinal disease to
ensure clinical decision-making is influ-
enced by the highest quality evidence.
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